TD Asset Management Inc lessened its stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) by 61.4% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,644 shares of the company's stock after selling 126,584 shares during the quarter. TD Asset Management Inc owned approximately 0.17% of CARGO Therapeutics worth $324,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Red Tree Management LLC bought a new stake in CARGO Therapeutics in the 4th quarter valued at $30,293,000. TRV GP VI LLC purchased a new position in shares of CARGO Therapeutics during the fourth quarter valued at about $26,924,000. TRV GP V LLC bought a new stake in shares of CARGO Therapeutics in the fourth quarter worth about $25,051,000. Peapod Lane Capital LLC purchased a new stake in shares of CARGO Therapeutics in the first quarter worth about $892,000. Finally, Janus Henderson Group PLC lifted its position in shares of CARGO Therapeutics by 5.8% in the fourth quarter. Janus Henderson Group PLC now owns 2,830,544 shares of the company's stock worth $40,859,000 after buying an additional 155,259 shares in the last quarter. Institutional investors own 93.16% of the company's stock.
CARGO Therapeutics Price Performance
Shares of CARGO Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $4.49. The company's stock had a trading volume of 726,630 shares, compared to its average volume of 1,184,925. The firm has a 50 day moving average price of $4.45 and a 200-day moving average price of $4.63. The stock has a market cap of $206.80 million, a P/E ratio of -0.97 and a beta of 0.30. CARGO Therapeutics, Inc. has a one year low of $3.00 and a one year high of $25.45.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group raised their price target on CARGO Therapeutics from $3.70 to $5.00 and gave the company a "hold" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, CARGO Therapeutics has a consensus rating of "Hold" and a consensus target price of $15.40.
Read Our Latest Analysis on CRGX
CARGO Therapeutics Profile
(
Free Report)
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Featured Stories

Before you consider CARGO Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.
While CARGO Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.